Kornimate/medical-research-clean huggingface dataset:
different manufacturing techniques of facial prostheses

Conditions: Facial Defects

Summary: all participants will undergo 3-dimentional facial scan and the defect site will be scanned using intraoral scanner. the data will be extracted in standard tessellation language (stl) and used in virtual prosthesis reconstruction. * (group 1) involves direct printing of the final prosthesis using biocompatible rubber-like printable soft resin. * group 2, involves direct manufacturing of the negative mold, it will be virtually designed based on an inverted stl file of prosthesis prototype/ pattern. * group 3, involves fabrication of the negative mold indirectly by printing the prosthesis prototype from resin and then duplicating it into wax and a conventional stone mold will be fabricated. * the negative molds of both groups 2\&3 will be used in packing medical grade silicone (to cast the final prosthesis. * all final prostheses will be colored and characterized to match the surrounding anatomy. * esthetic outcomes will be assessed using vas scale by answering operator and patient related questionnaires. the patient related questionnaire will be translated to the patients and responses will be recorded. for each patient, a score will be given from 1-5. * prosthesis accuracy will be assessed using medit software, comparing the scan of the final prosthesis to the stl of the prosthesis design and the root mean square (rms) will be recorded.


Eligibility criteria:
inclusion criteria: 1. patients with cartilaginous facial defects, i.e: auricular and nasal defects. 2. patients between 20-60 years old. 3. post traumatic patients with facial defects. 4. patients with congenital facial defects. 5. patients with failed facial surgical construction. 6. compliant and cooperative patients. exclusion criteria: 1 - patients having risk of tumor recurrence in the defect area. 2- patients undergoing radiotherapy or chemotherapy treatment. 3- patients with any debilitating disease. 4- patients with any type of psychosomatic disorder. 5- patients with allergy to any of the materials used.
korean multicenter randomized controlled trial (rct) of pidogul for patients with coronary stenting

Conditions: Coronary Artery Disease

Summary: the aim of the current study is to compare the antiplatelet efficacy and safety of clopidogrel napadisilate and clopidogrel bisulfate in coronary artery disease (cad) patients after coronary stent implantation.


Eligibility criteria:
inclusion criteria: * korean men and women between the age of 20 and 85 * patients who were diagnosed as having cad * patients who were planned to undergo pci exclusion criteria: * patients who were not treated with pci or intended to treat with pci but failed * patients who were were taking or had taken other antiplatelet or anticoagulant for more than 2 weeks within the prior 30 days * patients who were had a history of alcohol abuse or intoxication; (4) had hypersensitivity to clopidogrel or aspirin * patients who were had hypersensitivity to clopidogrel or aspirin * patients who were had abnormal laboratory results indicative of liver disease * patients who were had blood coagulation disorders, uncontrolled severe hypertension, active bleeding, or history of severe bleeding, such as intracranial hemorrhage or ulcer bleeding * patients who were were pregnant, breastfeeding, or not using effective methods of contraception * patients who were had other contraindication to study drug * patients who were had participated in another clinical study within 4 weeks prior to the start of this study

Keywords: cad pci percutaneous coronary intervention
effect of exercise-based rehabilitation on circulatory functions in patients with diastolic heart failure

Conditions: Heart Failure

Summary: the purpose of this study is to investigate how exercise-base rehabilitation influences circulatory functions in patients with diastolic heart failure (dhf).

a quasi-experimental design will be used in this investigation. eighty dhf patients will be recruited from chang gung medical foundation, keelung branch after they have provided informed consent. these subjects will be randomized into the trained (n=40) and the control groups (n=40). the trained subjects will be trained on a bicycle ergometer at about 60-70%of heart rate reserve for 35-55 minutes (that will include 10-min warm-up, 15-35-min main exercise, and 10-min cool-down) per day, 3 days per week for 12 weeks. the control subjects will maintain their normal living pattern. subjects' physical fitness, oxygen transport and utilization of exercising skeletal muscles, cardiovascular functions and hemodynamics, blood cell parameters, rbc deformity and aggregation, plasma biomarkers of myocardial damage, and thrombotic factors/reactions will be measured at pre-training stage and following the 8th and 12th week of the training program. experimental results were analyzed by descriptive statistics (percentage, mean, and standard deviation), independent t-test, two-way anova, and two-way ancova. previous researches were mainly focus on systolic heart failure, less on diastolic heart failure. we study the above parameter to realize the physiological response to exercise of these patients and discover the appropriate exercise intensity for prescription.

Eligibility criteria:
inclusion criteria: * cardiac event with optimal medial treatment within 3 months and have 4 more weeks spared from heart disease attack or major cardiac procedure. * lvef\>50% exclusion criteria: * unstable angina pectoris, * uncompensated heart failure, * myocardial infarction during the past 4 weeks, * complex ventricular arrhythmias, * orthopedic or neurological limitations to exercise.

Keywords: exercise-base rehabilitation diastolic heart failure cardiovascular function aerobic fitness
safety study of 90y-hmn14 to treat colorectal cancer patients with limited residual disease after surgery

Conditions: Colorectal Neoplasms

Summary: the purpose of this trial is to determine the safety of 90y-hmn14 at different dose levels in the treatment of residual colorectal cancer following recent surgery.


Eligibility criteria:
disease characteristics: * patients with documented histologic and cytologic diagnosis of colon or rectal malignancy * patients with documented status post surgical resection of primary cancer or metastases * limited residual disease (i.e., cea serum levels \ 1 cm) prior/concurrent therapy: * patients must have completed chemotherapeutic agents, biologic therapy, radiotherapy, other investigational therapy for cancer, or surgical procedures at least six weeks prior to study entry. * patients must have recuperated from surgery and toxicities (as a result of previous therapy) sufficiently prior to study entry * biologic therapy: patients who have received a murine, chimeric, cdr-grafted (humanized), or human igg will be eligible provided pre-study evaluations demonstrate no significant reactivity with hmn-14 igg (i.e., haha) * radiotherapy: no prior external beam irradiation to a field that includes more than 30% of the red marrow. no prior radiation to maximal tolerable levels for any critical organs (e.g., 3000 cgy for the liver; 2000 cgy for the lungs and kidneys) patient characteristics/inclusion criteria: * performance status: patients with karnofsky performance status \> 70% * hematopoietic: anc \>/= 1.5 x 10/l; hemoglobin \>/= 10 g/dl; platelets \>/= 100 x 10/l * renal: serum creatinine \</= 1.5 x uln * hepatic: serum bilirubin \</= 1.5 uln; ast and alt \</= 2.5 x uln; alk phosphatase \</= 2.5 x uln * cardiovascular: patients with lvef \>/= 50% by required muga/2d-echo tests * pulmonary: patients with df and fev1 \>/= 60% by required pulmonary function tests * central nervous system: patients with known metastatic disease to the cns are excluded. * other: patients agreeing to use a medically effective method of contraception during and for a period of three months after the treatment period. a pregnancy test will be preformed on each premenopausal female of childbearing potential immediately prior to entry into study. patients must understand and give written informed consent.

Keywords: colorectal cancer colon cancer rectal cancer colorectal neoplasms colorectal carcinoma colorectal tumor
effects of dietary fiber on glucose control in subjects with type 2 diabetes mellitus

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of this study is to determine the effect of a commercial dietary fiber supplement on patients with type 2 diabetes mellitus, in the way of glucose control, insulin action in the body, and the gut microbiota (bacteria) abundance.

fiber supplements such as psyllium are known to be beneficial to glycemic control in patients with type 2 diabetes mellitus (t2dm). gut microbiota has a role in regulating host energy metabolism and systemic inflammation by several pathways such as short-chain fatty acid production, fasting-induced adipose factor expression, endocannabinoid system, and gut epithelial permeability. as dietary components can influence the composition of the microbiota, we hypothesized that fiber supplements could modify gut microbiota and consequently affect glycemic control and inflammatory condition in patients with t2dm. the primary outcome was to assess the effect of fiber on glucose control (by comparing fasting glucose and glycoalbumin), insulin secretion and sensitivity. secondary outcomes were the changes abundance of microbiota, incretins, and lipopolysaccharide (lps).

Eligibility criteria:
inclusion criteria (all of the followings): * among type 2 diabetic patients who visit diabetes center at samsung medical center * 2 or more of following are required: 1. use of lipid-lowering drugs and / or triglyceride ≥ 150 mg/dl, high-density lipoprotein \< 40 mg/dl in men and \< 50 mg/dl in women 2. waist circumference \> 90 cm in men and \> 80 cm in women 3. antihypertensive medication and / or blood pressure ≥ 130/85 mmhg * hemoglobin a1c level 7.0 - 9.0% (6.5 - 9.0% in age 50-60 years old) * patients who are treated with combination therapy of sulfonylurea and metformin at least 6 months and in steady-glucose-controlled state. exclusion criteria (at least one of the followings): * patients using insulin, alpha-glucosidase inhibitor, meglitinide, thiazolidinedione, or incretin agent (both oral or injectables) * recently diagnosed (within 6 months) acute diabetic complication such as diabetic ketoacidosis and hyperosmolar hyperglycemic state * clinically significant cardiovascular disease * patients treated with oral or intravenous antibiotics last 12 months * patients who took fiber supplements last 6 months * fasting serum c-peptide level \< 1 ng/ml * duration of type 2 diabetes \> 10 years

Keywords: dietary fiber microbiota diabetes mellitus, type 2 metformin sulfonylurea compounds
analysis of tumor deposit at the fusion site of the right gastric mesentery and left gastric mesentery in the patients with gastric cancer who received proximal gastrectomy

Conditions: Gastric Carcinoma

Summary: this study aims to evaluate the tumor deposit at the fusion site of the right gastric mesentery and left gastric mesentery in the patients with gastric cancer who received proximal gastrectomy.

in the 6th edition of the japanese gastric cancer treatment guidelines; during proximal gastrectomy, d2 lymphadenectomy includes nodes no. 1, no. 2, no. 3a, no. 4sa, no. 4sb, no. 7, no. 8a, no. 9, no. 11p, and no. 11d. when performing d2 surgery for proximal gastric cancer, the dissection typically includes no. 3a (lymph nodes along the branches of the left gastric artery, including those below the cardia branch) and no. 7 (distributed along the left gastric artery from its root to the bifurcation of the ascending branch), while not including the no. 5 group nodes (located in the upper region of the pylorus between the root of the right gastric artery and the first branch of the gastric wall). in d2 lymphadenectomy plus complete mesogastric excision (cme) for proximal gastric cancer, a complete resection of the left gastric mesentery is performed without removing the right gastric mesentery. however, clinical observations have shown that there may be a fusion between the left and right gastric mesenteries. merely excising the left gastric mesentery could potentially lead to tumor residue or recurrence in the right mesentery. this study aims to investigate tumor deposit at the fusion site of the right gastric mesentery and left gastric mesentery following d2+cme surgery for proximal gastric cancer, intending to provide evidence-based medical insights for standardizing lymph node clearance in gastric cancer.

Eligibility criteria:
inclusion criteria: 1. aged older than 18 years and younger than 85 years 2. primary gastric adenocarcinoma confirmed by preoperative pathology result 3. ct2-4an0-3m0 at preoperative evaluation according to the american joint 8 committee on cancer (ajcc) cancer staging manual 8th edition 4. patients undergoing proximal gastrectomy with d2 lymphadenectomy plus complete mesogastric excision 5. american society of anesthesiologists (asa) class i, ii, or iii 6. written informed consent exclusion criteria: 1. negative preoperative biopsy 2. too late tumour stage or metastasis (ct4b/m1) 3. bmi\>30 kg/m2 4. previous neoadjuvant chemotherapy or radiotherapy 5. previous upper abdominal surgery 6. combined with other malignant diseases 7. reject operation

Keywords: gastric cancer lymph node dissection right gastric mesentery tumor deposit
maternal weight gain in gestational diabetes controlled by metformin versus insulin

Conditions: Gestational Diabetes

Summary: insulin has many disadvantages for mothers with gdm including the need to give injections, frequent daily testing for monitoring, and risks of hypoglycemia, increase in appetite, weight gain and high cost. metformin, an oral biguanide, may be a more logical alternative to insulin for women with gdm who are unable to cope with the increasing insulin resistance of pregnancy. this study aim to compare maternal weight gain during pregnancy in women with gestational diabetes, treated by insulin versus metformin.


Eligibility criteria:
inclusion criteria: * patients aged (19-35) years * bmi 18-30 kg/m2 * gestational age \>24 weeks * singleton pregnancy * gestational diabetes mellitus with failure to achieve adequate glucose control on diet therapy alone (fbg \> 105) or patients with gestational diabetes who are controlled with either metformin alone or insulin alone. exclusion criteria: * pregnant women with preexisting diabetes mellitus * women who have contraindication to take metformin e.g.: impaired renal function, hepatic cirrhosis, hepatitis). * patients with other medical disorders that could affect perinatal outcome (e.g., hypertension, sle etc). * fetal anomalies identified on ultrasound prior to initiation of therapy. * patients who refused to participate
lyophilized black raspberries in adults with familial adenomatous polyposis (fap)

Conditions: Familial Adenomatous Polyposis

Summary: this is a 36 week dietary intervention pilot study to evaluate the effects of lyophilized black raspberries on rectal polyp burden and biomarkers in subjects with fap. subjects will undergo a colonoscopy or sigmoidoscopy before study treatment to determine eligibility for the study. eligible participants will undergo a sigmoidoscopy at 36 weeks after the initiation of study treatment. the size and number of rectal polyps will be documented on a code sheet and by photograph. the efficacy outcome will include the percentage reduction in the number of rectal polyps between baseline and 36 weeks.


Eligibility criteria:
inclusion criteria: * diagnosis of familial adenomatous polyposis with at least 5 rectal polyps which are greater than or equal to 2 mm on baseline colonoscopy * have an endoscopically assessable rectal segment * have not taken nsaids or selective cox-2 inhibitors for two months prior to the study and willing to remain off nsaids for the study duration. exclusion criteria: * known allergies or hypersensitivity to berries * diabetes mellitus * subjects taking nsaids or cox-2 inhibitors who cannot be taken off the medication due to their clinical condition.

Keywords: polyp, familial adenomatous polyposis, prevention
bioequivalence and lack of food effects of 300mg lamotrigine xr

Conditions: Epilepsy

Summary: this study intends to demonstrate bioequivalence and lack of food effect on 300mg lamotrigine xr in healthy male and female volunteers


Eligibility criteria:
inclusion criteria: * body weight \>50 kg (males) or \>45 kg (females) and bmi within the range 19 - 29.9 kg/m2 inclusive. * healthy as determined by a responsible physician, based on a medical evaluation including history, physical examination, laboratory tests, vital signs and ecg. a subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the investigator considers that the finding will not introduce additional risk factors and will not interfere with the study procedures. exclusion criteria: * female subjects of childbearing potential will not be eligible to participate who are unwilling or unable to use an appropriate method of contraception as outlined in the inclusion criteria from at least the commencement of their last normal period prior to the first dose of study medication; and to continue until the first normal period (defined as normal for the woman, both in terms of duration and quantity of menses) after treatment or 5 half lives of the study medication, whichever is the longest. * female subject is pregnant (positive serum human chorionic gonadotrophin (hcg) test at screening) or lactating. * female subjects using hormonal contraceptive precautions including progesterone-coated iud * female subjects using hormonal replacement therapy. * subjects who received lamotrigine in a previous study (subjects who received placebo will be allowed). * current smokers of 10 or more cigarettes per day.

Keywords: healthy volunteers bioequivalence food effects
awareness, care & treatment in obesity management - an international observation

Conditions: Obesity

Summary: the purpose of this survey is to collect the data on perceptions, behaviours and awareness related to obesity and obesity management for people with obesity (pwo) and health care professionals (hcp) treating obesity. data will be collected via online surveys among each of the respondent groups. the surveys are expected to take approximately 25 minutes to complete and will be unique for pwo and hcp. as a cross-sectional study, there will be no treatment of patients.


Eligibility criteria:
inclusion criteria: - people with obesity - age at least 18 years, both males and females - on-line consent to participate in study - lives in one of the participating countries: italy, spain, united kingdom (uk), brazil, chile, mexico, australia, israel, saudi arabia, united arab emirates (uae), japan, south korea - current body mass index (bmi) (based on self-reported height and weight) greater than or equal to 30 kg/sqm in italy, spain, uk, brazil, chile, mexico, australia, israel, saudi arabia, uae; current bmi greater than or equal to 25 kg/sqm in japan and south korea - health care professionals - physician - specialty is not plastic surgeon, general surgeon, or bariatric surgeon - practices in one of the participating countries: italy, spain, uk, brazil, chile, mexico, australia, israel, saudi arabia, uae, japan, south korea - in practice at least 2 years - spends at least 70 percent of time in direct patient care - has seen at least 100 patients in past month - has seen at least 10 patients in past month needing weight management defined as: a patient with a bmi greater than or equal to 30 kg/sqm with or without comorbidities. (bmi greater than or equal to 25 kg/sqm in japan and south korea) exclusion criteria: - people with obesity - declines to provide income - previous participation in this study. participation is defined as having given online consent in this study - declines to provide race / ethnicity (in applicable countries) - currently pregnant - participates in intense fitness or body building programs - has had significant, unintentional weight loss (due to major injury, illness, etc.) in the past 6 months
mri split scar sign as a predictor to complete pathologic response after neoadjuvant chemoradiation in rectal cancer

Conditions: Rectum Cancer

Summary: patients with middle or low rectal cancer who receive neoadjuvant chemoradiation and achieve complete clinical response while their pelvic mri have split scar sign are included. patients will have total mesorectal excision and pathologic complete response will be assessed

patients with middle or low rectal cancer who have t3-4 and/ or n+ will be included. patients will receive neoadjuvant chemoradiation in the form of pelvic irradiation by 50.4 thousands grays together with radio sensitization by 5-fu or oxaliplatin, 8 months after completion of neoadjuvant chemoradiation patients will be assessed clinically and radiologically. complete clinical response is diagnosed if clinically no tumor is felt or just small scar and no tumor appears in mri. of these patients who achieve complete clinical response we will pick up cases who have split scar sign in the pelvic mri. patients will have total mesorectal excision 8-11 weeks after completion of neoadjuvant chemoradiation and pathologic complete response will be assessed. correlation will be done between preoperative clinical response and postoperative pathologic response

Eligibility criteria:
inclusion criteria: middle and low rectal cancer exclusion criteria: * distant metastasis
dressing wear time after reduction mammaplasty

Conditions: Surgical Site Infection; Skin Colonization

Summary: this study was designed to determine whether the duration of dressing wear following reduction mammaplasty influence skin colonization and surgical site infections rates.

surgical site infections (ssi) are wound infections that occur after invasive procedures.particularly in plastic surgery procedures, to minimize the risk of ssi is imperative, since even minor infections are able to complicate the healing process and harm the cosmetic result. reduction mammaplasty is an effective and well established procedure performed for the relief of physical pain and discomfort associated with macromastia, which significantly decreases patients' quality of life.breast reduction has provided long-term relief for most patients, with high patient satisfaction. the demand for this kind of plastic surgery is high.reduction mammaplasty was the fifth most commonly surgical procedure performed by plastic surgeons in women of united states.since reduction mammaplasty is associated with a high incidence of wound problems,all effort to minimize the risk of ssi is valid.

Eligibility criteria:
inclusion criteria: * breast hypertrophy * candidate to reduction mammaplasty * body mass index under 30kg/m2 exclusion criteria: * pregnancy, delivery or breast feeding during the last 12 months * body mass index over 30kg/m2 * breast cancer history * previous breast surgery * hard smoking

Keywords: breast hypertrophy mammaplasty bandages surgical site infection skin colonization
observational study to evaluate the safety of levemir® in patients with diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2

Summary: this study is conducted in europe. the aim of the study is to observe the safety of insulin detemir (levemir®) in patients with type 1 and type 2 diabetes patients.


Eligibility criteria:
inclusion criteria: * any patient with type 1 or type 2 diabetes mellitus, including newly diagnosed patients who had never received insulin or an insulin analogue before exclusion criteria: * patients whom the physician considered might be noncompliant for any reason; for example, uncooperative attitude, inability to return for the final visit and similar * patients previously enrolled in this study * patients with a hypersensitivity to insulin detemir